Europe Dog Dewormers Market Size, Key Companies, Company Market Share, Patient Volume, Treatment Adoption Rates, Pricing Analysis, Regulatory Landscape, Competitive Positioning, and Demand Forecast

Europe Dog Dewormers Market Size, Share and Forecast 2026-2035

The Europe dog dewormers market is estimated at USD 596.40 million in 2026 and is projected to reach USD 1,222.34 million by 2035, expanding at a CAGR of 8.3% from 2026 to 2035.

Key Takeaways

Market Size & Growth Outlook

• Market size in 2026: USD 596.40 million
• Estimated market size in 2027: USD 645.90 million
• Projected market size by 2036: USD 1,222.34 million
• CAGR (2026-2035): 8.30%

Regional Market Spotlight

• Germany led the market with a 19.60% (USD 107.63 million) share in 2025
• United Kingdom accounted for 17.80% (USD 97.75 million) of the market in 2025.
• France accounted for 15.40% (USD 84.58 million) of the market in 2025.
• Poland accounted for 5.60% (USD 30.75 million) in 2025 and is projected to be the fastest-growing country, at a CAGR of 10.12% from 2026 to 2035.

Segmental Spotlight

• By product type, Multi-Ingredient Broad-Spectrum (Praziquantel/Pyrantel/Febantel) accounted for 36.80% (USD 202.10 million) in 2025.
• By dosage form, Tablets accounted for 54.20% (USD 297.65 million) in 2025.
• By type, Prescription accounted for 63.70% (USD 349.82 million) in 2025.
• By distribution channel, Veterinary Clinics & Hospitals accounted for 49.80% (USD 273.49 million) in 2025

Europe Dog Dewormers Market Size and Forecast, 2025-2035 (USD Million)

The was valued at USD 596.40 million in 2026, the base year and it comprises the anthelmintic tablets, chewables, and spot-ons used to control roundworms, tapeworms, hookworms, whipworms and heartworms in dogs across European countries. Multi-ingredient broad-spectrum dewormers accounted for the largest product share in 2025, at 36.8% as praziquantel-based combinations remain the routine choice for quarterly worming. Germany is estimated to account for 19.6% of revenue in 2025, supported by one of Europe's largest dog populations and high veterinary spending.

Demand is driven by rising dog ownership, more frequent deworming guided by veterinary recommendations and the shift to monthly combination of parasiticides. New endectocide combinations, such as Credelio Plus and the growth of online pet pharmacies, are reshaping competition.

Note: 2025 is the base year; 2026-2035 values are forecasts.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

The Europe dog dewormers market is projected to grow from USD 596.40 million in 2026 to USD 1,222.34 million by 2035 because more European dog owners deworm regularly and more of them choose higher-priced monthly combination products. Rising dog ownership and easier repeat purchasing through online pharmacies add volume, lifting the market to USD 820.45 million by 2030 and sustaining a CAGR of 8.30% from 2026 to 2035.

• Analyst View: Our estimate of Europe dog dewormers is built from the number of dogs in each country, the share that are dewormed, the average number of treatments per year, and manufacturer price per dose by product type. Pet population inputs draw on FEDIAF data, which counts about 299 million pets across 139 million European households, and treatment frequency reflects the gap between veterinary guidance and actual owner behavior. We cross-checked the total against the animal health revenues of major suppliers and published estimates. The growth rate reflects rising treatment frequency and the shift to higher-priced monthly combination of products rather than strong growth in dog numbers.

Market Trends

• Monthly isoxazoline-based endectocides are replacing separate flea, tick, and worm treatments.
• Veterinarians are moving owners from twice-yearly to quarterly or monthly deworming schedules.
• Online pet pharmacies are growing repeat dewormer sales through subscriptions.
• Generic praziquantel-based tablets are expanding in price-sensitive markets.
• Palatable chewable formats are improving owner compliance.
• Rising awareness of zoonotic worms such as Echinococcus is supporting routine treatment.

Drivers, Restraints and Opportunities

Driver

Rising dog ownership and veterinary advice on regular deworming are boosting the market growth. Annual parasite programs are replacing occasional worming, especially where lungworm and heartworm risk is rising. Pet humanization also makes owners more willing to pay for convenient, palatable products.

Restraint

Generic competition keeps prices low for routine broad-spectrum tablets. Many owners still treat less often than veterinary guidance recommends, which limits volume growth. Prescription rules in some countries also restrict how easily combination products can be sold outside clinics.

Opportunity

Monthly combination endectocides that cover worms, fleas, and ticks raise spending per dog and simplify treatment for owners. Online pharmacies and subscription models make repeat purchases easier and improve compliance. Central and Eastern European markets offer additional growth due to rising awareness of veterinary care.

Market Segmentation: 2025 Share and Value

Europe Dog Dewormers Market by Product Type 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Multi-ingredient broad-spectrum dewormers accounted for an estimated 36.80% (USD 202.10 million) in 2025 because praziquantel, pyrantel, and febantel tablets kill the common worms in single dosage. Milbemycin oxime combinations, at 26.40% (USD 144.98 million), grow on added heartworm and lungworm protection. isoxazoline-based endectocides is at 19.6% (USD 107.63 million), as owners choose one monthly product for fleas, ticks and worms. Benzimidazoles such as fenbendazole, at 9.30% (USD 51.08 million), are used for puppies and multi-day treatment courses. Macrocyclic lactone spot-ons, at 5.10% (USD 28.01 million). These are specially designed for dogs that refuse tablets, and other products account for 2.80% (USD 15.38 million).

Europe Dog Dewormers Market by Dosage Form 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Tablets accounted for an estimated 54.20% (USD 297.65 million) in 2025, the standard form for generic and branded wormers. Chewables, at 27.90% (USD 153.22 million), gained largest share because palatable monthly products improve owner compliance, while spot-ons, at 12.80% (USD 70.29 million), are specifically for dogs that refuse oral treatment. Pastes, liquids and granules, at 5.10% (USD 28.01 million) and are mainly used for puppies and small dogs that need flexible dosing. The shift to palatable chewable is supported by monthly combination products, as they are easier to give.

Europe Dog Dewormers Market by Type 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Prescription products accounted for an estimated 63.7% (USD 349.82 million) in 2025 and are growing faster as veterinarians recommend combination endectocides. Over-the-counter wormers, at 36.3% (USD 199.35 million), keep a steady base through pharmacy and pet store sales of praziquantel-based tablets. Prescription products carry higher prices because they include combination endectocides and heartworm prevention. Over-the-counter tablets remain important for price-sensitive owners and routine quarterly worming.

Europe Dog Dewormers Market by Distribution Channel 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Veterinary clinics and hospitals accounted for nearly half, 49.8% (USD 273.49 million) in 2025 because most combination products are prescribed during routine visits. Online pharmacies and e-commerce, at 30.7% (USD 168.59 million), gain share on subscription repeat orders, while retail pharmacies and pet stores, at 19.5% (USD 107.09 million), serve OTC demand. Online growth is supported by repeat-purchase reminders and subscription models, while veterinary clinics keep control of prescription decisions. Retail channels remain strongest in countries with broad OTC availability, such as the Netherlands and the UK.

• Analyst View: Segment shares were derived from the product portfolios and pricing of leading brands in each country. Broad-spectrum praziquantel-based tablets lead because they are the routine quarterly choice, while milbemycin and isoxazoline combinations carry higher prices per dose because they add heartworm, lungworm, flea, or tick protection. Channel shares reflect where prescription and over-the-counter products are sold in each market. We expect value to shift toward prescription combinations and chewable formats as veterinarians move owners to annual programs.

Country Analysis

Europe Dog Dewormers Market by Country 2025 Share & Size

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Germany accounted for an estimated 19.60% (USD 107.63 million) in 2025, growing on one of Europe's largest dog populations and high veterinary spending. The United Kingdom, at 17.80% (USD 97.75 million), grows with strong online pharmacy adoption, while France, at 15.40% (USD 84.58 million), expands on routine preventive care, and Poland, at 5.60% (USD 30.75 million), is the fastest-growing country. Italy, at 10.90% (USD 59.86 million), and Spain, at 9.20% (USD 50.52 million), rely more on annual heartworm and combination products, while the Nordics, at 4.70% (USD 25.81 million), and the Netherlands, at 4.10% (USD 22.51 million), are developed markets shaped by strict prescription rules or strong OTC channels.

Germany accounted for an estimated 19.60% (USD 107.63 million) in 2025. The country has one of Europe's largest dog populations and high veterinary spending, supporting strong uptake of prescription combination products.

The United Kingdom accounted for an estimated 17.80% (USD 97.75 million) in 2025. High online pharmacy adoption and strong awareness of lungworm driving regular deworming support the segmental growth.

France accounted for an estimated 15.40% (USD 84.58 million) in 2025. Routine preventive care and a large pet pharmacy network across the region support steady demand for broad-spectrum wormers.

Italy accounted for an estimated 10.90% (USD 59.86 million) in 2025. Heartworm-endemic areas drive demand for annual macrocyclic lactone and combination products.

Spain accounted for an estimated 9.20% (USD 50.52 million) in 2025. Warm climate and heartworm risk support monthly endectocide use, while rising dog ownership adds volume.

Poland accounted for an estimated 5.60% (USD 30.75 million) in 2025 and is the fastest-growing country. Rising dog ownership, more veterinary visits, and growing pet spending lift demand.

The Nordics accounted for an estimated 4.70% (USD 25.81 million) in 2025. Prescription rules and test-based deworming keep volumes moderate but support premium products.

The Netherlands accounted for an estimated 4.10% (USD 22.51 million) in 2025. Strong OTC and pet store channels support broad-spectrum tablet sales.

The Rest of Europe accounted for an estimated 12.70% (USD 69.74 million) in 2025. Central and Eastern European markets drive growth as pet care spending rises.

• Analyst View: Country shares combine national dog populations, veterinary spending per dog, and the mix of prescription and over-the-counter products. Germany, the UK and France lead because they combine large dog populations with high veterinary spending. Poland receives the highest growth premium in our forecast because dog ownership and veterinary visits are rising from a lower base, while Southern European markets gain support from heartworm risk that requires annual protection.

Top 10 Companies in the Europe Dog Dewormers Market

Note: Company revenues and shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Elanco led the Europe dog dewormers market with an estimated 16.53% (USD 90.79 million) of 2025 revenue, followed by Boehringer Ingelheim at 15.90% (USD 87.29 million) and Zoetis at 12.17% (USD 66.85 million). Elanco leads with Milbemax, Advocate and Credelio Plus, Boehringer Ingelheim with NexGard Spectra, and Zoetis with Simparica Trio, while Vetoquinol owns the European rights to Drontal and Profender. The top 10 companies accounted for an estimated 75.37% (USD 413.90 million) of 2025 revenue, while the remaining 24.63% (USD 135.27 million) was shared among generic manufacturers, private-label and pharmacy brands. Competition is moving toward a monthly combination of products that provide worm control along with flea and tick protection, while generic makers such as Krka compete on price in praziquantel-based tablets.

Recent Developments

• June 2025: FEDIAF published its Facts and Figures 2025 report, counting about 299 million pets and 139 million pet-owning households in Europe.
• January 2026: French company Agrobiothers launched a range of repellent parasite-control pipettes and sprays for dogs and cats in European markets under its Vetocanis Laboratoire and Bogar brands.
• 2026: Krka reported 2025 animal health product sales of EUR 114.7 million, up about 3%, with most sales coming from companion animal products.

Market Segments

By Product Type

• Multi-Ingredient Broad-Spectrum (Praziquantel/Pyrantel/Febantel)
• Milbemycin Oxime Combinations
• Isoxazoline-Based Endectocide Combinations
• Benzimidazoles (Fenbendazole and Others)
• Macrocyclic Lactone Spot-ons
• Others

By Dosage Form

• Tablets
• Chewables
• Spot-on
• Pastes, Liquids & Granules

By Type

• Prescription
• Over-the-Counter
• By Distribution Channel
• Veterinary Clinics & Hospitals
• Online Pharmacies & E-commerce
• Retail Pharmacies & Pet Stores

By Country

• Germany
• United Kingdom
• France
• Italy
• Spain
• Poland
• Nordics
• Netherlands
• Rest of Europe

Research Methodology

The Europe dog dewormers market was defined as dog anthelmintics sold in Europe at manufacturer level, including combination parasiticides with wormer claims. The 2025 base year was built bottom-up from the dog population, treated share, treatments per year and price per dose, and verified against company revenues and published estimates. Segment, country, and company values were allocated from product portfolios, channel data and national pet populations, then reconciled before publication. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party predictions, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2026 estimate through 2035, was recalculated and validated.

Analyst View Overall Market

Dog deworming in Europe is moving from an occasional tablet to a planned, annual parasite program, which lifts both treatment frequency and price per dose. Our estimate is driven by canine population, treatment frequency, and product mix, so the forecast depends more on how owners treat. Monthly combination products are pulling value toward prescriptions, while generic praziquantel tablets keep the volume base. The main risks are generic price erosion, owner compliance gaps, and pressure on household spending.

Sources and References

• FEDIAF - European Pet Food Industry. "FEDIAF publishes 2025 Facts and Figures". 2025-06-12. About 299 million pets and 139 million pet-owning households in Europe. (Source: https://europeanpetfood.org/ )
• European Commission - Union Product Database. "Credelio Plus veterinary medicine record". Undated. Authorised combination parasiticide for dogs. (Source: https://medicines.health.europa.eu)
• Zoetis Inc. (SEC EDGAR). "Form 10-K, fiscal year 2025". 2026. Companion animal parasiticide portfolio including Simparica Trio. (Source: https://www.sec.gov)
• Krka, d. d., Novo mesto. "FY25 Results Presentation". 2026. Animal health product sales of EUR 114.7 million in 2025, mostly companion animals. (Source: https://www.krka.biz)
• Pet Food Processing. "FEDIAF: thriving pet ownership fuels European pet food industry". 2025. European pet ownership trends. (Source: https://www.petfoodprocessing.net)
• Vet Times. "Zoetis' Simparica Trio licensed to treat lungworm". 2025-08-18. UK lungworm licence for Simparica Trio. (Source: https://www.vettimes.com/news/vets/small-animal-vets/zoetis-simparica-trio-licensed-to-treat-lungworm
• MSD Animal Health (Merck Animal Health). "Merck Animal Health announces European approval of Bravecto TriUNO for use in dogs". 2024-11-26. EU authorisation of fluralaner, moxidectin and pyrantel combination for dogs. (Source: https://www.merck-animal-health.com)
• Pet Business World. "Drontal sale given green light". 2020-06-11. European Commission approval of the divestment of Drontal and Profender to Vetoquinol. (Source: https://www.petbusinessworld.co.uk)